Search
Ingo K. Mellinghoff, MD, FACP, neuro-oncologist and Chair of the Department of Neurology, presented significant results from a phase III trial in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Read about Josh Foromera, who was born in a small village in Zimbabwe and recently began a fellowship in the Gastroenterology, Hepatology, and Nutrition Service at MSK.
The Coalition was discussed at the fourth annual Bloomberg New Economy Forum (NEF) in Singapore on November 16–19.
For the first time, scientists have determined the extent of DNA repair deficiencies across cancer types. Learn what it means for patients.
The immune system is a powerful tool for fighting cancer — sometimes too powerful.
Three Gerstner Sloan Kettering students -- Marta Kovatcheva, Isabel Lam, and Elizabeth Wasmuth -- have been awarded grants that recognize their academic and research excellence.
For some patients with metastatic melanoma, a combination of two immunotherapies works better than either drug alone.
MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine.
With the resurgence of interest in cancer metabolism, researchers are coming to realize that there is more to a cell’s biochemistry than once thought.
MSK’s Francesca Gany emphasized the need to overcome the digital and linguistic divides between the healthcare system and communities.